Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
 Your new post is loading...
Your new post is loading...
Scoop.it!
Pfizer Inc. announced today that it will present data for several of its marketed and investigational medicines for inflammatory and immunological conditions at the American College of Rheumatology (ACR) / Association of Rheumatology Health Professionals (ARHP) 2014 Annual Meeting (November 14-19, Boston, Massachusetts). Via Krishan Maggon 
Scoop.it!
The IFNα-Kinoïd is an anti interferon alpha (IFNα) therapeutic vaccine developed for the treatment of lupus (or Systemic Lupus Erythematosus, SLE).
Via Krishan Maggon
Krishan Maggon 's curator insight,
August 16, 2014 9:41 PM
The French company has been looking for R&D partners for IFNα-Kinoïd since 2011. After Rontalizumab Phase II failure and discontinuation by Roche , it has become more difficult to fund lupus research. |
Scoop.it!
Purpose of reviewGenome-wide association studies have identified more than 50 robust loci associated with systemic lupus erythematosus (SLE) susceptibility, and follow-up studies help reveal candidate causative genetic variants and their biological relevance contributing to the development of SLE... Via Krishan Maggon
|
Improvement of disease activity and reduction of severe flares following subcutaneous administration of an IL-6 monoclonal antibody (mAb) in subjects with active generalized systemic lupus erythematosus (SLE)." Wallace DJ, Popa S, Spindler AJ, et. al. [Presentation L3; November 18, 2014 5:00 p.m. - 5:15 p.m.]
Add to the Body of Evidence for XELJANZ® (Tofacitinib Citrate) as a Treatment Option for Adults with Moderate to Severe Rheumatoid Arthritis- - - Efficacy Results from a Phase 2 Study of Anti-IL-6 in Patients with Systemic Lupus Erythematosus- - - Phase 1 Abstracts for Two Pfizer Biosimilars in Development; Both Assets Move into Phase 3 Comparability Trials